The INFECIR-2 Albumin Prevention Study

NCT02034279 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

136

Enrollment

OTHER

Sponsor class

Stopped Low recruitment rate and expiration of the study drug

Conditions

Advanced Chronic Liver Disease
Urinary Infection
Pneumonia
Cholangitis
Other Bacterial Diseases

Interventions

DRUG: Albumin

Sponsor

EASL - CLIF Consortium